Investor Relations

Financial Releases

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Announces FDA Approval of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
Product Offers Targeted Relief for Managing Chronic Condition MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 11, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it has received approval from the
View HTML
Toggle Summary Intersect ENT to Present at the 36th Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 7, 2017-- Intersect ENT, Inc. (Nasdaq: XENT ), today announced that management will present an overview of the company's business at the 36 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 2:30 p.m. PT at the Westin St.
View HTML
Toggle Summary FDA Performs Pre-Approval Inspection of Intersect ENT’s Menlo Park Facility
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the U.S. Food and Drug Administration ( FDA ) has performed a Pre-Approval Inspection
View HTML
Toggle Summary Intersect ENT to Present at the Piper Jaffray 29th Annual Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 3, 2017-- Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company’s business at the 29 th Annual Piper Jaffray Healthcare Conference in New York . The presentation is scheduled for 4:00pm ET on November 28,
View HTML
Toggle Summary Intersect ENT Announces a Pivotal Study Publication of PROPEL® Contour Steroid Releasing Sinus Implant
Study Builds on the Extensive Clinical Evidence for Steroid Releasing Sinus Implants MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 2, 2017-- Intersect ENT, Inc. (NASDAQ: XENT) today announced a pivotal study publication of the second cohort of the prospective, randomized, blinded, multi-center
View HTML
Toggle Summary Intersect ENT Reports Third Quarter 2017 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 2, 2017-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2017 .
View HTML
Toggle Summary Intersect ENT to Report Third Quarter 2017 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 16, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its third quarter on November 2, 2017 .
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2017 Results
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2017 .
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2017 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 1, 2017-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2017 .
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2017 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its second quarter on August 1, 2017 .
View HTML